Hypera (HYPE3) Aperçu de l'action
Hypera S.A. est une entreprise pharmaceutique au Brésil. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 1/6 |
| Santé financière | 2/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hypera S.A. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | R$22.67 |
| Plus haut sur 52 semaines | R$28.87 |
| Plus bas sur 52 semaines | R$20.66 |
| Bêta | 0 |
| Variation sur 1 mois | -3.49% |
| Variation sur 3 mois | -4.87% |
| Variation sur 1 an | -6.32% |
| Variation sur 3 ans | -43.87% |
| Variation sur 5 ans | -37.05% |
| Évolution depuis l'introduction en bourse | 171.50% |
Nouvelles et mises à jour récentes
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Recent updates
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).HYPE3: Slight Index Exit And Firm P/E Outlook Will Support Upside
Analysts have nudged their price target for Hypera slightly lower to reflect small adjustments in fair value, discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a modest trim of about R$0.15 per share. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how some index and benchmark aware investors treat the stock (Key Developments).HYPE3: Future P/E Multiple Expansion Will Support Further Upside Potential
Analysts have slightly increased their price target on Hypera to reflect updated fair value estimates and adjustments to revenue growth, profit margin expectations, and future P/E assumptions. What's in the News Hypera S.A. is scheduled to hold a board meeting on Dec 11, 2025, which may address governance, capital allocation, or operational planning (company event filing).Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...HYPE3: Future P E Expansion Will Support Further Upside Potential
Analysts have slightly raised their price target on Hypera to $30.24 from $30.14, citing modestly stronger revenue growth expectations that more than offset a small downward revision in projected profit margins and a higher implied future P/E multiple. Valuation Changes Fair Value Estimate has risen slightly from R$30.14 to R$30.24 per share, reflecting a modestly higher intrinsic valuation.What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Hypera...HYPE3: Future P/E Expansion Signals Continued Upside Potential
Analysts have increased their price target for Hypera from $29.59 to $30.14, citing revised estimates that reflect a slightly higher discount rate as well as updated projections for revenue growth and profit margin. Valuation Changes Fair Value: Increased slightly from R$29.59 to R$30.14 per share.Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Hypera S.A.'s ( BVMF:HYPE3 ) stock showed strength, with investors undeterred by its weak earnings report. We think...Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Hypera S.A. ( BVMF:HYPE3 ), who've watched their investment drop 10% to R$23.19 in the week...The Price Is Right For Hypera S.A. (BVMF:HYPE3)
With a price-to-earnings (or "P/E") ratio of 21.7x Hypera S.A. ( BVMF:HYPE3 ) may be sending very bearish signals at...Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hypera S.A.'s ( BVMF:HYPE3 ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
With a median price-to-earnings (or "P/E") ratio of close to 8x in Brazil, you could be forgiven for feeling...More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
To the annoyance of some shareholders, Hypera S.A. ( BVMF:HYPE3 ) shares are down a considerable 27% in the last month...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
There wouldn't be many who think Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10x is worth a...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10.9x right now seems...Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Hypera S.A. ( BVMF:HYPE3 ) had a good week, as its shares rose 3.3% to close at R$34.10 following the...Is Hypera (BVMF:HYPE3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 12.7x right now seems...Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Is Hypera (BVMF:HYPE3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 13x might make it look like a sell right now...Rendement pour les actionnaires
| HYPE3 | BR Pharmaceuticals | BR Marché | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | -0.7% |
| 1Y | -6.3% | 20.5% | 15.0% |
Rendement vs Industrie: HYPE3 a sous-performé le secteur BR Pharmaceuticals qui a rapporté 20.5 % au cours de l'année écoulée.
Rendement vs marché: HYPE3 a sous-performé le marché BR qui a rapporté 15 % au cours de l'année écoulée.
Volatilité des prix
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 8.4% |
| 10% least volatile stocks in BR Market | 1.9% |
Cours de l'action stable: HYPE3 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché BR.
Volatilité au fil du temps: La volatilité hebdomadaire de HYPE3 ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1999 | 10,564 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. est une société pharmaceutique brésilienne. Elle propose des produits de prescription sous les marques Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma et velunid. L'entreprise propose également des produits de protection solaire et de soins hydratants pour la peau sous les marques Mantecorp Skincare, des produits similaires sous les marques Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum et Torsilax ; et des médicaments en vente libre sous les marques Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil et Neosaldina, ainsi que des médicaments similaires et génériques sous la marque Neo Química.
Hypera S.A. Résumé des fondamentaux
| HYPE3 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | R$15.95b |
| Bénéfices(TTM) | R$1.20b |
| Recettes(TTM) | R$7.70b |
Le site HYPE3 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HYPE3 compte de résultat (TTM) | |
|---|---|
| Recettes | R$7.70b |
| Coût des recettes | R$3.15b |
| Marge brute | R$4.55b |
| Autres dépenses | R$3.35b |
| Les revenus | R$1.20b |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Aug 06, 2026
| Résultat par action (EPS) | 1.70 |
| Marge brute | 59.04% |
| Marge bénéficiaire nette | 15.53% |
| Ratio dettes/capitaux propres | 74.6% |
Quelles ont été les performances à long terme de HYPE3?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 08:48 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Hypera S.A. est couverte par 22 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |